Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Reimbursement Incentives to Improve Adherence to Follow-Up of Cervical Cancer Cytology Screening Results in Peru.

Ferris DG, Chen J, Isaac A, Braithwaite E, Beideck E, Mikail N, Krotish D, Waller JL.

J Low Genit Tract Dis. 2019 Apr;23(2):116-123. doi: 10.1097/LGT.0000000000000459.

PMID:
30741754
2.

Improved anal Cytology Sampling: Tush Brush Compared With Dacron Swab.

Ferris DG, Darragh TM, Kavuri S, Patel N, Waller JL, Goebel A.

J Low Genit Tract Dis. 2019 Jan;23(1):48-53. doi: 10.1097/LGT.0000000000000447.

PMID:
30407936
3.

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.

Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsagué X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Muñoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C.

Obstet Gynecol. 2018 Aug;132(2):261-270. doi: 10.1097/AOG.0000000000002736.

PMID:
29995724
4.

Evidence of Influence of Human Activities and Volcanic Eruptions on Environmental Perchlorate from a 300-Year Greenland Ice Core Record.

Cole-Dai J, Peterson KM, Kennedy JA, Cox TS, Ferris DG.

Environ Sci Technol. 2018 Aug 7;52(15):8373-8380. doi: 10.1021/acs.est.8b01890. Epub 2018 Jul 9.

PMID:
29943569
5.

4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years.

Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, Chatterjee A, Iversen OE, Joshi A, Chu JL, Krick AL, Saah A, Das R.

Pediatrics. 2017 Dec;140(6). pii: e20163947. doi: 10.1542/peds.2016-3947.

6.

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.

Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonego J, Muñoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Papillomavirus Res. 2016 Dec;2:61-69. doi: 10.1016/j.pvr.2016.03.002. Epub 2016 Mar 14.

7.

Reaching women in the Peruvian Andes through cervical cancer screening campaigns: assessing attitudes of stakeholders and patients.

Luque JS, Maupin JN, Ferris DG, Guevara Condorhuaman WS.

Patient Prefer Adherence. 2016 Oct 18;10:2107-2116. eCollection 2016.

8.

Change Suboptimal Tactics and Promote a National Mandatory Human Papillomavirus Vaccination Program.

Ferris DG.

J Low Genit Tract Dis. 2016 Oct;20(4):348-351. No abstract available.

PMID:
27482798
9.

Social network characteristics and cervical cancer screening among Quechua women in Andean Peru.

Luque JS, Opoku S, Ferris DG, Guevara Condorhuaman WS.

BMC Public Health. 2016 Feb 24;16:181. doi: 10.1186/s12889-016-2878-3.

10.

Salud es Vida: a Cervical Cancer Screening Intervention for Rural Latina Immigrant Women.

Luque JS, Tarasenko YN, Reyes-Garcia C, Alfonso ML, Suazo N, Rebing L, Ferris DG.

J Cancer Educ. 2017 Dec;32(4):690-699. doi: 10.1007/s13187-015-0978-x.

11.

Polarized Light Colposcopy Compared With Standard Colposcopy.

Ferris DG, Condorhuaman WS, Waller JL, Allmond L, Goebel A.

J Low Genit Tract Dis. 2015 Jul;19(3):234-8. doi: 10.1097/LGT.0000000000000111.

12.

The Impact of Accessible Cervical Cancer Screening in Peru-The Día del Mercado Project.

Ferris DG, Shapiro J, Fowler C, Cutler C, Waller J, Guevara Condorhuaman WS.

J Low Genit Tract Dis. 2015 Jul;19(3):229-33. doi: 10.1097/LGT.0000000000000112.

PMID:
25943865
13.

Impact of a Video Intervention for Rural Peruvian Women With Cervical Neoplasia Before Loop Excisional Procedures.

Ferris DG, Condorhuaman WS, Waller J, Lilienthal A.

J Low Genit Tract Dis. 2015 Jul;19(3):224-8. doi: 10.1097/LGT.0000000000000107.

PMID:
25856124
14.

Mobile fiber-optic sensor for detection of oral and cervical cancer in the developing world.

Yu B, Nagarajan VK, Ferris DG.

Methods Mol Biol. 2015;1256:155-70. doi: 10.1007/978-1-4939-2172-0_11.

PMID:
25626538
15.

Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population.

Castle PE, Smith KM, Davis TE, Schmeler KM, Ferris DG, Savage AH, Gray JE, Stoler MH, Wright TC Jr, Ferenczy A, Einstein MH.

Am J Clin Pathol. 2015 Jan;143(1):126-33. doi: 10.1309/AJCP4Q0NSDHWIZGU.

PMID:
25511151
16.

Cultural beliefs and understandings of cervical cancer among Mexican immigrant women in Southeast Georgia.

Luque JS, Tarasenko YN, Maupin JN, Alfonso ML, Watson LC, Reyes-Garcia C, Ferris DG.

J Immigr Minor Health. 2015 Jun;17(3):713-21. doi: 10.1007/s10903-014-0117-5.

17.

Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy.

Einstein MH, Smith KM, Davis TE, Schmeler KM, Ferris DG, Savage AH, Gray JE, Stoler MH, Wright TC Jr, Ferenczy A, Castle PE.

J Clin Microbiol. 2014 Jun;52(6):2089-95. doi: 10.1128/JCM.00176-14. Epub 2014 Apr 9.

18.

Diffuse reflectance spectroscopy of epithelial tissue with a smart fiber-optic probe.

Yu B, Shah A, Nagarajan VK, Ferris DG.

Biomed Opt Express. 2014 Feb 10;5(3):675-89. doi: 10.1364/BOE.5.000675. eCollection 2014 Mar 1.

19.

Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males.

Goldstone SE, Jessen H, Palefsky JM, Giuliano AR, Moreira ED Jr, Vardas E, Aranda C, Hillman RJ, Ferris DG, Coutlee F, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner E.

Vaccine. 2013 Aug 20;31(37):3849-55. doi: 10.1016/j.vaccine.2013.06.057. Epub 2013 Jul 2.

PMID:
23831322
20.

Multimodal hyperspectroscopy as a triage test for cervical neoplasia: pivotal clinical trial results.

Twiggs LB, Chakhtoura NA, Ferris DG, Flowers LC, Winter ML, Sternfeld DR, Lashgari M, Burnett AF, Raab SS, Wilkinson EJ.

Gynecol Oncol. 2013 Jul;130(1):147-51. doi: 10.1016/j.ygyno.2013.04.012. Epub 2013 Apr 13.

PMID:
23591399
21.

Comparison of cyanide exposure markers in the biofluids of smokers and non-smokers.

Vinnakota CV, Peetha NS, Perrizo MG, Ferris DG, Oda RP, Rockwood GA, Logue BA.

Biomarkers. 2012 Nov;17(7):625-33. doi: 10.3109/1354750X.2012.709880. Epub 2012 Aug 13.

PMID:
22889346
22.

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.

Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM; FUTURE I and II Study Group.

BMJ. 2012 Mar 27;344:e1401. doi: 10.1136/bmj.e1401.

23.

Comparison of knowledge and attitudes toward human papillomavirus, HPV vaccine, pap tests, and cervical cancer between US and Peruvian women.

Han CS, Ferris DG, Waller J, Tharp P, Walter J, Allmond L.

J Low Genit Tract Dis. 2012 Apr;16(2):121-6. doi: 10.1097/LGT.0b013e31823a05a3.

PMID:
22227842
24.

Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.

Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Vardas E, Aranda C, Jessen H, Ferris DG, Coutlee F, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI.

Clin Vaccine Immunol. 2012 Feb;19(2):261-7. doi: 10.1128/CVI.05208-11. Epub 2011 Dec 7.

25.

Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.

Ferris DG, Waller J, Dickinson A, McCracken C, Goebel A.

J Low Genit Tract Dis. 2012 Jan;16(1):39-44. doi: 10.1097/LGT.0b013e31822e8e25.

PMID:
22126831
26.

Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies.

Baker DA, Ferris DG, Martens MG, Fife KH, Tyring SK, Edwards L, Nelson A, Ault K, Trofatter KF, Liu T, Levy S, Wu J.

Infect Dis Obstet Gynecol. 2011;2011:806105. doi: 10.1155/2011/806105. Epub 2011 Aug 24.

27.

Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.

Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, Lehtinen MO, Steben M, Joura EA, Giacoletti KE, Radley DR, James MK, Saah AJ, Sings HL; FUTURE I and II Investigators.

Int J Cancer. 2011 Dec 1;129(11):2632-42. doi: 10.1002/ijc.25940. Epub 2011 Apr 13.

28.

Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia.

Lehtinen M, Ault KA, Lyytikainen E, Dillner J, Garland SM, Ferris DG, Koutsky LA, Sings HL, Lu S, Haupt RM, Paavonen J; FUTURE I and II Study Group.

Sex Transm Infect. 2011 Aug;87(5):372-6. doi: 10.1136/sti.2010.044354. Epub 2011 Apr 6.

29.

The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.

Brown DR, Garland SM, Ferris DG, Joura E, Steben M, James M, Radley D, Vuocolo S, Garner EI, Haupt RM, Bryan JT.

Hum Vaccin. 2011 Feb;7(2):230-8. Epub 2011 Feb 1.

PMID:
21307649
30.

Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Hernandez-Avila M, Brown DR, Elbasha E, Muñoz N, Paavonen J, Haupt RM; FUTURE I Investigators.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):287-96. doi: 10.1158/1055-9965.EPI-10-0791.

31.

Cervical biopsy sampling variability in ALTS.

Ferris DG, Litaker MS.

J Low Genit Tract Dis. 2011 Apr;15(2):163-8. doi: 10.1097/LGT.0b013e3181f2ddf3.

PMID:
21169866
32.

Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men.

Goldstone S, Palefsky JM, Giuliano AR, Moreira ED Jr, Aranda C, Jessen H, Hillman RJ, Ferris DG, Coutlee F, Liaw KL, Marshall JB, Zhang X, Vuocolo S, Barr E, Haupt RM, Guris D, Garner EI.

J Infect Dis. 2011 Jan 1;203(1):66-74. doi: 10.1093/infdis/jiq016.

33.

External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents.

Vardas E, Giuliano AR, Goldstone S, Palefsky JM, Moreira ED Jr, Penny ME, Aranda C, Jessen H, Moi H, Ferris DG, Liaw KL, Marshall JB, Vuocolo S, Barr E, Haupt RM, Garner EI, Guris D.

J Infect Dis. 2011 Jan 1;203(1):58-65. doi: 10.1093/infdis/jiq015.

34.

Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.

Ault KA, Joura EA, Kjaer SK, Iversen OE, Wheeler CM, Perez G, Brown DR, Koutsky LA, Garland SM, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Majewski S, Muñoz N, Sings HL, Harkins K, Rutkowski MA, Haupt RM, Garner EI; FUTURE I and II Study Group.

Int J Cancer. 2011 Mar 15;128(6):1344-53. doi: 10.1002/ijc.25723. Epub 2011 Jan 12.

35.

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.

BMJ. 2010 Jul 20;341:c3493. doi: 10.1136/bmj.c3493.

36.

Most parents do not think receiving human papillomavirus vaccine would encourage sexual activity in their children.

Ferris DG, Cromwell L, Waller JL, Horn L.

J Low Genit Tract Dis. 2010 Jul;14(3):179-84. doi: 10.1097/LGT.0b013e3181d41806.

PMID:
20592552
37.

Enhancing colposcopy with polarized light.

Ferris DG, Li W, Gustafsson U, Lieberman RW, Galdos O, Santos C.

J Low Genit Tract Dis. 2010 Jul;14(3):149-54. doi: 10.1097/LGT.0b013e3181d52f59.

PMID:
20592547
38.

Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women.

Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, Joura EA, Ferris DG, Steben M, Brown DR, Elbasha EH, Paavonen J, Haupt RM; FUTURE I Investigators.

Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1585-94. doi: 10.1158/1055-9965.EPI-09-1235.

39.

The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials.

Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, Joura EA, Djursing H, Sigurdsson K, Jefferson L, Alvarez F, Sings HL, Lu S, James MK, Saah A, Haupt RM; FUTURE I, II and III Investigators.

Int J Cancer. 2011 Mar 15;128(6):1354-62. doi: 10.1002/ijc.25470.

40.

Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology.

Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, Olson MC.

Gynecol Oncol. 2010 Aug 1;118(2):116-22. doi: 10.1016/j.ygyno.2010.04.013. Epub 2010 May 21.

PMID:
20488510
41.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
42.

Opinions of parents about school-entry mandates for the human papillomavirus vaccine.

Horn L, Howard C, Waller J, Ferris DG.

J Low Genit Tract Dis. 2010 Jan;14(1):43-8. doi: 10.1097/LGT.0b013e3181b0fad4.

PMID:
20040835
43.

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.

Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Hum Vaccin. 2009 Oct;5(10):696-704. Epub 2009 Oct 1.

PMID:
19855170
44.

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.

45.

Use of the VS-sense swab in diagnosing vulvovaginitis.

Sobel JD, Nyirjesy P, Kessary H, Ferris DG.

J Womens Health (Larchmt). 2009 Sep;18(9):1467-70. doi: 10.1089/jwh.2008.1305.

PMID:
19743911
46.

Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPV.

Mast TC, Zhu X, Demuro-Mercon C, Cummings HW, Sings HL, Ferris DG.

Curr Med Res Opin. 2009 Nov;25(11):2609-19. doi: 10.1185/03007990903238786.

PMID:
19739938
47.

Large-scale analysis of protein expression changes in human keratinocytes immortalized by human papilloma virus type 16 E6 and E7 oncogenes.

Merkley MA, Hildebrandt E, Podolsky RH, Arnouk H, Ferris DG, Dynan WS, Stöppler H.

Proteome Sci. 2009 Aug 23;7:29. doi: 10.1186/1477-5956-7-29.

48.

Using acetowhite opacity index for detecting cervical intraepithelial neoplasia.

Li W, Venkataraman S, Gustafsson U, Oyama JC, Ferris DG, Lieberman RW.

J Biomed Opt. 2009 Jan-Feb;14(1):014020. doi: 10.1117/1.3079810.

49.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):926-35. doi: 10.1086/597307.

PMID:
19236279
50.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.

Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):936-44. doi: 10.1086/597309.

PMID:
19236277

Supplemental Content

Loading ...
Support Center